Unique ID issued by UMIN | UMIN000005768 |
---|---|
Receipt number | R000006819 |
Scientific Title | Prospective study of laparoscopic adjustable gastric banding with MIDBAND system for morbidly obese patients |
Date of disclosure of the study information | 2011/06/13 |
Last modified on | 2013/06/15 16:18:14 |
Prospective study of laparoscopic adjustable gastric banding with MIDBAND system for morbidly obese patients
Prospective study of LAGB with MIDBAND system for morbid obesity
Prospective study of laparoscopic adjustable gastric banding with MIDBAND system for morbidly obese patients
Prospective study of LAGB with MIDBAND system for morbid obesity
Japan |
Patients for whom gastric banding was indicated will be included in the study. Exhaustive and consecutive inclusions of 20 patients will be carried out at Yotsuya Medical Cube with the MIDBAND implant.
Surgery in general | Gastrointestinal surgery | Endocrine surgery |
Others
NO
To evaluate the effectiveness of the MIDBAND, whose original characteristics looks promising in terms of effectiveness, post-operative comfort, and prevention of complications.
Safety,Efficacy
Change in weight loss (BMI and percentage of excess weight loss)
Change in obesity-related comorbidity status, change in quality of life
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Device,equipment | Maneuver |
Laparoscopic adjustable gastric banding
18 | years-old | <= |
Not applicable |
Male and Female
1, age over 18
2, resistant to medical management of weight loss
3, BMI over 30kg/m2
4, written consent for the study
(1) Cardiovascular event in the past 6 months. (2) Current evidence of congestive heart failure, angina pectoris, or symptomatic peripheral vascular disease. (3) Cardiac stress test indicating that surgery would not be safe. (4) Pulmonary embolus or thrombophlebitis in the past 6 months. (5) Cancer of any kind unless documented to be disease-free for 5 years. (6) Significant anemia (hemoglobin 1.0 g or
more below normal range) or history of coagulopathy. (7) Serum creatinine 2.0 mg/dl or more. (8) History of stomach surgery, bile duct surgery, pancreatic surgery, splenectomy, or colon resection. (9) Gastric or duodenal ulcer in the past 6 months. (10) History of intra-abdominal
sepsis. (11) Self-reported HIV-positive status, active tuberculosis, active malaria, chronic hepatitis B or C,
cirrhosis, or inflammatory bowel disease. (12) Currently pregnant or nursing, or planning to become pregnant in the next 2 years. (13) History of alcohol or drug dependency in the past 5 years. (14) Active psychosocial or psychiatric problem that is likely to interfere with adherence to the protocol. (15)
Presence of any chronic or debilitating disease that would make adherence to the protocol difficult. (16) Exclusions may also be made at the discretion of the attending physician.
20
1st name | |
Middle name | |
Last name | Kazunori Kasama |
Yotsuya Medical Cube
Weight Loss and Metabolic Surgery Center
7-7 Nibancho, Chiyoda-ku, Tokyo
1st name | |
Middle name | |
Last name |
Yotsuya Medical Cube
Weight Loss and Metabolic Surgery Center
yosuke_seki@hotmail.com
Yotsuya Medical Cube
MID(Medical Inovation et Developpement, Dardilly, France)
Profit organization
France
NO
2011 | Year | 06 | Month | 13 | Day |
Unpublished
No longer recruiting
2011 | Year | 05 | Month | 09 | Day |
2011 | Year | 06 | Month | 01 | Day |
2011 | Year | 06 | Month | 13 | Day |
2013 | Year | 06 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006819